Price
No data yet.
Social Signal Score
Revenue
$647.0K-68.04%Company Profile
- CEO
- Greg Lipschitz
- Sector
- Technology
- Industry
- Software - Application
- Employees
- 17
- Beta
- 0.57
- Country
- US
- Piotroski score
- 4 / 9 (Middling)
- Altman Z-score
- -8.14
Financials
Revenue
$647.0K-68.0%Net Income
$-1.48M-729.9%EBITDA
$-1.48M-354.6%Free Cash Flow
$-1.20MEPS (diluted)
$-0.07-330.2%Shares Outstanding (diluted)
21.56M+173.9%Operating Expenses
$2.07MCash & Debt
$8.02MReturn of Capital
$0.00Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $1.14M | $-19.88M | $-1.86 |
| 2024 | $108.0K | $-10.46M | $-1.60 |
| 2023 | $498.0K | $-2.60M | $-0.33 |
| 2022 | $0.00 | $-3.79M | $-0.48 |
| 2021 | $32.0K | $-4.38M | $-0.56 |
| 2020 | $13.90M | $413.4K | $0.05 |
Valuation
AIFFhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
20-33.33%Social Signal Score
Mentions (5)
- Newsglobenewswire.com·5d ago·Negative
Firefly Neuroscience Reports 373% Year-Over-Year Increase in U18 ADHD Evoke™ Scans as Commercial Expansion Accelerates 4.7x expansion in scan volume bodes well for Firefly's recent commercial partnership to cross-sell non-drug treatment for pediatric ADHD across its growing nationwide network of Evoke™ clinical customers 4.7x expansion in scan volume bodes well for Firefly's recent commercial partnership to cross-sell non-drug treatment for pediatric ADHD across its growing nationwide network of
View source ↗ - Newsglobenewswire.com·26d ago·Positive
Firefly Neuroscience (NASDAQ: AIFF) Strengthens Non-Invasive Brain-Computer Interface Growth Strategy with Commercially Available Versus Platform – Firefly's AI foundation model, being built on more than 200,000 standardized EEG/ERP brain scans, bolsters its long-term BCI growth opportunity –
View source ↗ - Newsbenzinga.com·58d ago·Negative
Firefly Neuroscience and Neurosigma Partner To Expand Non-Drug Pediatric ADHD Care Firefly Neuroscience Inc. (NASDAQ:AIFF), an artificial intelligence company advancing precision neuroscience, partnered with NeuroSigma, Inc., a bioelectronic medical device firm, to expand clinician awareness and access to the Monarch eTNS System across the U.S.
View source ↗ - Newsglobenewswire.com·58d ago·Negative
Firefly (NASDAQ: AIFF) and NeuroSigma Partner to Expand Access to First FDA-Cleared, Non-Drug Treatment for Pediatric ADHD – Partnership will introduce NeuroSigma's second-generation Monarch eTNS ® System to Firefly's nationwide network of Evoke™ clinicians –
View source ↗ - Newsglobenewswire.com·66d ago·Negative
Firefly Neuroscience's Evoke™ Platform Selected to Bring Objective Brain-Function Insights to Radial's AI-Native Operating System for Brain Medicine – This integration of Firefly's FDA 510(k)-cleared, AI-powered EEG/ERP technology follows Radial's August 2026 acquisition of the management services organization supporting Mindful Health Solutions, forming the country's largest brain medicine clinical network –
View source ↗
Insider trading
Open-market buys and sells by AIFF officers and directors.
- Bought
- —
- Sold
- $1.0m
0 trades
10 trades
- Windsor Private Capital Lpsold
- Windsor Private Capital Lpsold
- Windsor Private Capital Lpsold
- Windsor Private Capital Lpsold
- Windsor Private Capital Lpsold
- Windsor Private Capital Lpsold
- Windsor Private Capital Lpsold
- Windsor Private Capital Lpsold
39 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in AIFF.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
